Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC). One hundr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2011-03, Vol.29 (8), p.1075-1082
Hauptverfasser: RUDIN, Charles M, MAUER, Ann, JANE QIAN, PRADHAN, Rajendra, DOWELL, Barry, KRIVOSHIK, Andrew, GORDON, Gary, SMAKAL, Martin, JUERGENS, Rosalyn, SPELDA, Stanislav, WERTHEIM, Michael, COATES, Andrew, MCKEEGAN, Evelyn, ANSELL, Peter, XIANGDONG ZHOU
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!